Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BAT8001 in HER2-Positive Solid Tumors
NCT04189211Phase 1Unknown
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Mar 2017
- Primary completion
- Dec 2019
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT8001 in breast cancer and gastric cancer (GC) (5 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 21 days, Maximum tolerated dose at 21 days and 5 more. Status: unknown.
02
Drugs
BAT8001
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT04189211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189211.